Evidence Builds for Immunotherapy Combos in SCLC

Ticiana A. Leal, MD
Published: Wednesday, Jan 10, 2018
VCUTiciana A. Leal, MD
Ticiana A. Leal, MD
 
Assistant Professor, Medicine
Team Leader, Thoracic Oncology Disease
Division of Hematology and Oncology
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Strategic Partnership
The most common systemic treatment for patients with small cell lung cancer (SCLC) in North America is a platinum/etoposide doublet chemotherapy. This regimen achieves a response rate of 50% to 70%, a median survival of 9 to 11 months, and a median 5-year survival rate of less than 5%.1,2 There has been no significant improvement in clinical outcomes for patients with extensive-stage SCLC, which represents about 70% of cases diagnosed in the United States, in the last 2 decades, making it one of the most fatal cancers.3
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x